聚焦"五谷"产业发展，从产业链式协同向集群、区域协同纵深推进。 近日，武汉市委十四届十二次全会审议通过了《中共武汉市委关于制定全市国民经济和社会发展第十五个五年规划的建议》和《关于全力打造"五个中心"全 面建设现代化大武汉的五年行动方案（2026—2030年）》。5日下午，武汉召开专题新闻发布会，亮出该市"五个中心"建设新阶段的行动指南。 "十五五"时期，武汉进入城市能级跃升期、优势转化加速期、转型发展关键期、区域协同发力期，将通过实施经济能级跃升行动、科技创新引领行动、现代 产业升级行动、开放枢纽提能行动、区域联动发展行动等七大行动，全面提升发展能级、发展质效、发展后劲。 根据目标，到2030年，武汉全市地区生产总值突破3万亿元，基本建成"五个中心"，现代化大武汉建设取得决定性进展。 本次武汉市委全会强调，以城市更新推动城市发展方式转变，带动经济发展方式转变。武汉市住房和城市更新局党组书记张灼在会上回答第一财经记者提问 时表示，武汉将实施既有建筑改造利用、老旧小区改造提质、老旧街区改造提升、老旧厂区改造焕新、城中村改造提速，建设"好房子、好小区、好社区、 好城区"。城市更新将由单一项目建设向整体功能提升转变 ...

Core Viewpoint - Benda Pharmaceutical's net profit for H1 2025 is projected to be 140 million yuan, a year-on-year decrease of 37.53%, primarily due to increased depreciation and amortization expenses impacting current profits [1] Financial Performance - The company's EBITDA stands at 498 million yuan, reflecting a year-on-year growth of 13.10%, indicating stable growth in core business operations [1] - The decline in net profit is attributed to rising costs, while the core business remains robust [1] Product Development and Market Position - Benda Pharmaceutical's drug sales are steadily increasing, reinforcing its competitive advantage in the lung cancer treatment market [1] - The first-line treatment of the third-generation EGFRTKI, Beifu Tini, is set to benefit from its inclusion in the medical insurance catalog, marking a significant milestone [1] - The company has received approval for postoperative adjuvant therapy indications, further expanding its treatment offerings [1] Future Prospects - Two KRAS-targeted drugs were showcased at the 2025 AACR, indicating promising future developments in the pipeline [1] - The company is actively enhancing its innovative product portfolio in the lung cancer sector and pursuing external collaborations, including the approval of plant-derived albumin for market entry [1] - The investment rating remains "Buy," reflecting confidence in the company's growth trajectory [1]